Our science
Human biology first, engineering second, marketing last. We start every program with evidence from people rather than with a molecule looking for a home.
Our research approach
A Baxtra program has to answer four questions before it is allowed to advance. What human evidence links this target to this disease? Which patients carry that biology? What measurement will show the intervention is doing what we think it is doing? And what result would make us stop?
The same four questions are asked of a surgical device, with the words changed: what clinical problem does this solve, for which procedures, what measurement proves it, and what would make us abandon the design. A joint review board of internal scientists, external advisers and practising clinicians applies the gates at candidate selection and again before any first-in-human use.
Since founding we have taken 26 discovery projects into that process. Four medicines and three devices survived it.
Platforms
Three discovery platforms
Targeted protein degradation
Molecular glues and bifunctional degraders that remove disease-driving proteins instead of inhibiting them — opening targets with no druggable pocket, including mutant oncoproteins.
Lead asset: BX-101 (KRAS G12D solid tumours)
Oral immune modulation
Small molecules against immune pathways that currently need injectable biologics, with tissue-level pathway profiling used to select patients rather than diagnosis codes alone.
Lead asset: BX-204 (Crohn’s disease)
Genetic medicines
Antisense oligonucleotides and siRNA for targets where human genetics gives an unambiguous direction of effect, delivered with conjugate chemistry for tissue selectivity.
Lead assets: BX-308 (ALS), BX-412 (lipoprotein(a))
Surgical engineering
Our device work is run out of a 24,000 square foot engineering and prototyping facility in Palm Beach Gardens that includes a full wet simulation lab. Surgeons operate on tissue models with our prototypes roughly every second week, and design changes come out of those sessions rather than out of a specification document.
Three disciplines carry the portfolio: intraoperative optical imaging, robotic soft-tissue instrumentation, and bioresorbable biomaterials. All three run under an ISO 13485-aligned quality system shared with the pharmaceutical side of the company.
Translational medicine
Translational medicine owns the question of whether a molecule does in people what it did in the lab. Every Baxtra first-in-human protocol carries a target-engagement readout — degradation percentage, receptor occupancy, CSF neurofilament, or plasma Lp(a) — before any efficacy endpoint is discussed.
- Dose selection driven by exposure–response modelling, not maximum tolerated dose alone
- Adaptive Phase 1b/2a designs with pre-specified futility rules written before dosing
- Biomarker analytics run in-house at Jupiter with externally qualified assays
- Device studies use the same statistical rigour as our drug trials, including blinded adjudication
Research ethics
Every human study Baxtra sponsors, drug or device, is reviewed by an independent institutional review board before a single participant is enrolled. We follow the Declaration of Helsinki and ICH Good Clinical Practice everywhere we operate.
Animal research
Some safety questions cannot yet be answered without animal studies. We apply the 3Rs, require a documented non-animal alternatives assessment for every protocol, and publish our annual numbers.
Informed consent
Consent documents are written to a plain-language standard and reviewed by patient advisers. Participants receive a lay summary of results when the study completes.
Conflicts of interest
Payments to clinicians and institutions are disclosed annually. Investigators may not hold equity in Baxtra while running a Baxtra-sponsored study, which matters more for a private company than a public one.
Surgeon advisers
Advisers who consult on device design are paid fair market value for their time, are named in resulting publications, and have no obligation to purchase or recommend our products.
Publications & data sharing
We register every interventional study before the first participant is enrolled and post results within 12 months of completion, whatever the outcome. As an eighteen-month-old company our published record is short — here is all of it.
| Publication | Journal | Date |
|---|---|---|
| Selective degradation of KRAS G12D with sparing of wild-type protein: preclinical characterisation of BX-101 | Journal of Medicinal Chemistry | Jun 2026 |
| Quantitative intraoperative perfusion imaging in colorectal anastomosis: a first-in-human feasibility study | Annals of Surgery | Apr 2026 |
| Oral TL1A antagonism in fibrostenotic Crohn’s disease: rationale and Phase 1 design | Inflammatory Bowel Diseases | Feb 2026 |
| A bioresorbable sealant for staple-line reinforcement: mechanical and degradation profile | Biomaterials | Dec 2025 |